GENFIT Prepares for Shareholders Meeting Focused on Liver Health
GENFIT, a committed biopharmaceutical company, is focused on improving the lives of patients suffering from rare and serious liver diseases. The company announced significant updates regarding its upcoming Combined General Meeting, set for June 17, 2025. This meeting is crucial for shareholder engagement and will unfold at the Faculty of Pharmaceutical Sciences.
Annual General Meeting Details
The shareholders will come together at 10:00 am (CET) to discuss pivotal developments and future plans about their innovative therapies. In an effort to keep shareholders informed, all relevant documentation will be accessible well ahead of the meeting, ensuring that stakeholders can make informed decisions.
Streamlining Voting for Shareholders
One of the highlights of this year's meeting is the introduction of the VOTACCESS platform, allowing shareholders to cast their votes online conveniently. GENFIT understands that in today’s digital age, streamlined processes are essential for ensuring that every voice is heard. Tutorials will be available to guide shareholders through this online voting system in a user-friendly manner, enriching their participation in the event.
Broadcast & Recording Availability
In an age where transparency is paramount, the Company will provide a live broadcast of the General Meeting on its website. Those who cannot attend can access a recording of the proceedings shortly thereafter. This demonstrates GENFIT's commitment to keeping stakeholders informed and maximally engaged, providing all shareholders with equal access to vital information.
About GENFIT and Its Mission
With over twenty years of experience in liver disease research, GENFIT has established itself as a leader in this field. The company focuses on addressing unmet medical needs in liver diseases, such as Acute-on-Chronic Liver Failure (ACLF). Its research pipeline includes multiple promising therapies targeting diverse mechanisms of action.
The company's development pipeline features several assets that aim to enhance treatment options for ACLF and other serious health conditions including cholangiocarcinoma, urea cycle disorders, and organic acidemias. One of their most notable advancements is Iqirvo, developed as a treatment for Primary Biliary Cholangitis (PBC) and approved by significant regulatory agencies.
Commitment to Innovation
As part of their ongoing commitment to innovation, GENFIT also focuses on developing diagnostic tools such as NIS2+ for metabolic dysfunction-associated steatohepatitis. These advancements reflect GENFIT’s dedication not only to medicinal therapies but also to improving diagnostic methodologies in liver health.
Company Background and Future Outlook
Headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA, GENFIT is widely recognized for its contributions to liver health and disease management. The company is publicly traded on both the Nasdaq Global Select Market and the Euronext regulated market, reinforcing its commitment to transparency and investor relations.
Moreover, in a significant development, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the company, which may enhance collaborative efforts in advancing liver disease treatment and innovation.
Frequently Asked Questions
What is the purpose of GENFIT's Combined Shareholders Meeting?
The meeting aims to inform shareholders about the company's developments and future strategies in addressing liver diseases.
How can shareholders participate in the voting process?
Shareholders can use the VOTACCESS platform to send their voting instructions online, along with supporting tutorials available on GENFIT's website.
Where will the General Meeting be held?
The General Meeting will be hosted at the Faculty of Pharmaceutical Sciences in Lille.
Will the General Meeting be accessible online?
Yes, the meeting will be broadcast live on GENFIT's website and be available for later viewing.
What is GENFIT's main focus as a company?
GENFIT focuses on developing treatments and diagnostic tools for patients with rare and life-threatening liver diseases, aiming to address significant unmet medical needs.
